![]() |
||||||||
|
Amgen is committed to helping provide comprehensive access for appropriate patients who may benefit from Neulasta® treatment. The
Neulasta FIRST STEP™ Program is intended to provide assistance to
eligible low-income patients who need help meeting their Neulasta®
co-insurance or co-payment requirement. |
|||||||
![]() |
||||||||
Important Program Information By using this card, the user acknowledges that the Neulasta FIRST STEP™ Program covers a portion of the patient's co-payment requirement associated with Neulasta® received and administered at a participatng doctor’s office or hospital. It does not cover other costs associated with the patient's visit or the cost of Neulasta® purchased at a pharmacy and then administered at the doctor’s office or hospital, or when the doctor’s office or hospital has not enrolled to participate in this program. |
||||||||
Indication and Important Safety Information Neulasta® (pegfilgrastim) is prescribed to reduce the risk of infection (initially marked by fever) in patients with some tumors receiving strong chemotherapy that decreases the number of infection-fighting white blood cells. IMPORTANT SAFETY INFORMATION In a clinical study, mild to moderate bone pain occurred in 31% of the patients taking Neulasta® and in 26% of the patients taking a placebo injection. In most cases, bone pain was controlled with a non-narcotic pain reliever, such as acetaminophen. Other common side effects reported by patients in the study taking either Neulasta® or placebo were consistent with the underlying cancer diagnosis and its treatment with chemotherapy, with the exception of bone pain. If you have any questions about this information, be sure to discuss them with your doctor. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Please see Prescribing Information and Patient Product Information |
||||||||